Published Research
Published Research
Neoantigen-Driven Targeting
Visualizing Synaptic Transfer of Tumor Antigens among Dendritic Cells
September 28, 2026Weill Cornell Medicine
Next-Gen Cell Therapies
Sotigalimab and/or nivolumab with chemotherapy in first-line metastatic pancreatic cancer: clinical and immunologic analyses from the randomized phase 2 PRINCE trial
September 4, 2026Dana-Farber Cancer Institute, The University of Pennsylvania, University of California, Los Angeles, University of California, San Francisco, The University of Texas MD Anderson Cancer Center
Neoantigen-Driven Targeting
Intratumoral CD4 + T Cells Mediate Anti-tumor Cytotoxicity in Human Bladder Cancer
September 4, 2026University of California, San Francisco
Next-Gen Cell Therapies
Overcoming T cell tolerance to tumor self-antigens through catch-bond engineering
March 19, 2026Stanford Medicine, University of California, Los Angeles
In Vivo Immune Engineering
In vivo site-specific engineering to reprogram T cells
March 18, 2026University of California, San Francisco, Gladstone Institutes
Systems Cancer Immunology
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trial
January 29, 2026Dana-Farber Cancer Institute, University of California, Los Angeles, University of Southern California, The University of Texas MD Anderson Cancer Center
Systemic dysfunction and plasticity of the immune macroenvironment in cancer models
May 25, 2020University of California, San Francisco
Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors
April 27, 2020Pooled Knockin Targeting for Genome Engineering of Cellular Immunotherapies
April 16, 2020University of California, San Francisco